CuraGen Gets Patents on Interactions Implicated in Cancer

March 2000
Biotech Business;Mar2000, Vol. 13 Issue 3, p2
Trade Publication
Reports that the United States Patent Office has granted two patents for CuraGen Corporation covering human protein interactions that have been implicated in the division and proliferation of cancer cells.


Related Articles

  • CuraGen Sells Cancer Drug to TopoTarget.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p3 

    The article reports on the cancer cell drug belinostat which CuraGen Corp. has sold its ownership to TopoTarget A/S for about $45 million in cash, stock and future milestone payments. It states that TopoTarget plans to move the product into a Phase III trial of belinostat in patients with...

  • Functional map completed. Dorey, Emma // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p246 

    Reports on the completion of the first functional genomics map of an entire genome by Connecticut-based Curagen Corp. in collaboration with Stanley Fields at the University of Washington, Seattle, Washington. Analysis of protein interactions in the yeast Saccharomyces cerevisiae; Implications...

  • CuraGen launches subsid. Grisham, Julie // Nature Biotechnology;Jul2000, Vol. 18 Issue 7, p700 

    Report on the launch of corporations to develop technologies for use in drug discovery, preclinical development and pharmacogenetics by New Haven, Connecticut-based CuraGen Corp. Possible development of software for using entire genome knowledge; Details of stakes of CuraGen.

  • CuraGen reports revenue increased 63% last year.  // Biotech Financial Reports;Mar2000, p1 

    Reports on the financial performance posted by New Haven, Connecticut-based biotechnology firm CuraGen Corp. for the fourth quarter and the year ended December 31, 1999. Pharmaceutical companies with which CuraGen established collaborations; Asset impairment charge; Application of genomics to...

  • CuraGen Shifts Focus, Cuts Jobs.  // Chemical Market Reporter;11/11/2002, Vol. 262 Issue 17, p4 

    Reports the reorganization at CuraGen Corp. as part of their drug development initiatives.

  • Curagen lays down markers, 120,000 of them. Hodgson, John // Nature Biotechnology;Oct99, Vol. 17 Issue 10, p951 

    Focuses on the database possessed by the Curagen Corp. that compiles several single-nucleotide polymorphisms and markers from human genome. Plans of the company to acquire patents for its database; Several associate companies of Curagen that take part in its research projects; Response of...

  • Targeting Growth.  // Pharmaceutical Executive;May2001, Vol. 21 Issue 5, p128 

    Reports on the discovery of a fibroblast growth factor protein by scientists at CuraGen in 2001.

  • News in brief.  // Nature;2/17/2000, Vol. 403 Issue 6771, p696 

    Reports on developments in scientific research as of February 17, 2000. European Commission's setting up of a benchmarking system to compare the scale and quality of research in the member countries of the European Union; Launching of the PubMed Central which gives access to the full text of...

  • Bayer, CuraGen in $1.5 Bn Drug Deal. Jarvis, Lisa // Chemical Market Reporter;01/22/2001, Vol. 259 Issue 4, p3 

    Provides information on an agreement of Bayer AG with CuraGen Corp. Terms of agreement; Remarks from Wolfgang Hartwig, executive vice-president of pharmaceuticals research at Bayer; Goals of the agreement.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics